Please enter the email address you used to register, then we will send you a link to choose a new password
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate o...
Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumors Emerging clinical profile f...
Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target...